An AbbVie schizophrenia drug acquired as part of a multi-billion dollar deal has failed two mid-stage studies, dealing a setback to the company’s plans to compete with a Bristol Myers Squibb ...

It’s a frustration for both doctors who treat patients with schizophrenia and for people living with it: the most effective antipsychotic drugs have side effects, so unpleasant patients would rather ...

The Food and Drug Administration approved the first new drug in over 30 years to treat schizophrenia in adults. The new drug Cobenfy, formerly known as KarXT, is manufactured by Bristol Myers Squibb, ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Cobenfy (xanomeline/trospium chloride; formerly KarXT) was ...

A mental health nurse has been struck off after taking drugs with a patient with schizophrenia. A committee found that ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...

In the months after 24-year-old D.J. was diagnosed with schizophrenia, he searched online for answers to questions that felt urgent and existential. Does it get really bad over time? Will I be able to ...

(NEW YORK) — From a pig kidney transplant to restoring genetic deafness, 2024 was a year full of medical breakthroughs. The breakthroughs include the discovery of a cause of an autoimmune disease, the ...

A new drug has been approved by Food Safety and Drug Administration (FDA) in September 2024 for schizophrenia, called the Cobenfy. As per the Yale Medicines of the Yale University, it is the first ...

Caplyta (lumateperone) is a prescription drug used to treat schizophrenia in adults. It does not come as a generic drug. Caplyta comes as an oral capsule. The active ingredient in Caplyta is ...